CUE Cue Biopharma, Inc. stock chart & analysis
Conviction 45HealthcareScan · Wed, Nov 18, 2026Cue Biopharma, Inc. (CUE) closed at $4.73 (+67.14%) on Nov 18, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 25, RS Rating 17, -89.6% from its 52-week high, -48.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
CUE technical analysis
Trend
CUE's moving averages are mixed — no clean uptrend or downtrend. It closed 79.1% below the 50-day ($22.61) and 78.0% below the 200-day ($21.53). ADX(14) at 21 points to a moderate trend. It meets 3 of 8 trend-template criteria.
Momentum
RSI(14) is 25, in oversold territory. MACD crossed below its signal line 2 sessions ago. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 17 puts its weighted 12-month performance ahead of about 17% of the US market.
Volume and volatility
Volume on the latest session ran 31.6× its 20-day average. It trades about $5.7M a day on average. ATR(14) is $2.98, 63.0% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.37) shows accumulation.
Key levels
The chart pattern's support is $16.40 and its resistance $29.00. The 52-week range is $2.83 to $45.50; price is 89.6% below the high and 67.1% above the low. The VWAP anchored at the 52-week high is $18.19, above price.
Performance
CUE returned -74.7% (1 week), -72.2% (1 month), -80.8% (3 months), -76.8% (6 months), -72.5% (1 year), -48.4% (year to date).
About Cue Biopharma, Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Pharmaceutical Preparations · Listed 2018 · 29 employees
Recent news
- CUE Reiterated by B. Riley Securities -- Price Target Lowered to $25GuruFocus · Wed, Nov 18, 2026
- Why Is Cue Biopharma (NASDAQ:CUE) Climbing 10% Pre-Market Today After Its Steep Slide?Kalkine · Wed, Nov 18, 2026
- Is Cue Biopharma (NASDAQ:CUE) In A Good Position To Deliver On Growth Plans?Simply Wall St · Wed, Nov 18, 2026
- B.Riley cuts Cue Biopharma stock price target on financing concernsInvesting.com UK · Wed, Nov 18, 2026
- Why Did Cue Biopharma (NASDAQ:CUE) Stock Sink After a USD 4.74 Quarterly Loss Per Share?kalkine.ca · Wed, Nov 18, 2026
- $CUE stock is down 70% today. Here's what we see in our data.Quiver Quantitative · Tue, Nov 17, 2026
- Why Did SELLAS Life Sciences (NASDAQ:SLS) Surge 163.69% While Cue Biopharma (NASDAQ:CUE) Fell 51.45% Among the Top 5 Biotech Movers, With Gain Therapeutics (NASDAQ:GANX), Cingulate (NASDAQ:CING) and Scilex Holding (NASDAQ:SCLXkalkine.ca · Tue, Nov 17, 2026
- What Is Driving the 51.45% Collapse at Cue Biopharma (NASDAQ:CUE)?kalkine.ca · Tue, Nov 17, 2026
- Why Did Cue Biopharma (NASDAQ:CUE) Report a Much Wider Third Quarter Loss?kalkine.ca · Tue, Nov 17, 2026
- (CUE) Risk Channels and Responsive AllocationStock Traders Daily · Tue, Nov 17, 2026
Insider activity
SEC Form 4 transactions in CUE · open-market 5 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Garzone Pamela Director · Common Stock · 2026-07-09 | Grant | 18.9K | — | 2026-07-09 | 2026-08-28 |
Sarraf Pasha Director · Common Stock · 2026-07-09 | Grant | 18.4K | — | 2026-07-09 | 2026-08-28 |
Meluzio Michael Vincent VP, Prin. Accounting Officer · Common Stock · 2026-08-13 | Exercise | 13.65K | — | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Exercise | 18.2K | — | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Sell | 2.38K | $70K | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Sell | 6.44K | $196K | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Sell | 4 | $125 | 2026-08-13 | 2026-08-17 |
Ray Sumita Chief Legal Compliance Officer · Common Stock · 2026-08-13 | Exercise | 18.2K | — | 2026-08-13 | 2026-08-17 |
Meluzio Michael Vincent VP, Prin. Accounting Officer · Common Stock · 2026-08-13 | Sell | 1.52K | $45K | 2026-08-13 | 2026-08-17 |
Meluzio Michael Vincent VP, Prin. Accounting Officer · Common Stock · 2026-08-13 | Sell | 4.11K | $125K | 2026-08-13 | 2026-08-17 |
SEC filings
EDGAR filings in CUE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.